Cancer’s intrinsic heterogeneity remains one of its most confounding challenges. Advanced malignancies such as breast, lung, and colorectal cancers frequently evade standardized treatments due to the uniqueness of every patient’s tumor biology, influenced by a convoluted interplay of genetic mutations, microenvironmental factors, and systemic physiological changes. Traditional methods for therapy selection often fail to account for this biological complexity and temporal evolution of disease, leading to suboptimal outcomes. The UC San Diego-led initiative addresses this gap by engineering Drug Recommender Engines (DREs), AI-powered tools designed to integrate and analyze multifaceted biological data continuously, enabling tailored therapy predictions that evolve alongside the tumor’s progression.

The technical innovation underlying these DREs rests on developing computational frameworks that marry high-dimensional omics datasets, imaging data, and clinical parameters to create a digital twin of the patient’s tumor landscape. This digital twin incorporates the dynamic signaling pathways, cellular heterogeneity, mutational burdens, and microenvironmental influences that characterize each malignancy. By iteratively updating these models with longitudinal patient data, the DREs aim to anticipate tumor adaptation mechanisms, including drug resistance, and suggest precision-guided therapeutic regimens that optimize efficacy while minimizing adverse effects.

Professor Trey Ideker, who spearheads this initiative, combines expertise in medicine, bioengineering, and computational sciences to drive this multidisciplinary research. His vision is to transcend conventional cancer diagnostics and therapeutics by leveraging AI’s predictive prowess, thus empowering clinicians with real-time decision-making tools. These technologies are anticipated not only to streamline the therapeutic selection process but also to uncover novel biomarkers and treatment vulnerabilities through predictive modeling, accelerating the pace of translational oncology.

The significance of developing such adaptive platforms is underscored by the epidemiology of advanced cancers in the United States, where over half a million patients now live with advanced or metastatic disease states. The unpredictable nature of tumor evolution and response to therapy necessitates technologies that are as dynamic as the disease itself. Through capturing real-time feedback loops in tumor biology and treatment response, the DREs are poised to become an integral component in achieving precision oncology at a population scale.

Integral to this endeavor is a collaborative framework involving a consortium of leading institutions, including City of Hope, University of Washington, University of California San Francisco, University of Minnesota, alongside biotech innovators Unravel Genomics and Serinus Biosciences. This cross-institutional partnership synergizes cutting-edge research in genomics, systems biology, machine learning, and clinical oncology to validate and deploy the digital tumor platforms. The convergence of diverse scientific domains ensures robustness and translational potential in diverse clinical settings.

This project is a vital part of the broader ARPA-H ADAPT program, which represents a $142 million commitment towards personalized and adaptive cancer care. The ADAPT program prioritizes the utilization of emergent technologies and deep biological insights to refine treatment modalities over time, thereby moving beyond static therapeutic regimens toward dynamic, patient-specific interventions. The program supports not only computational tools but also first-of-its-kind clinical trials and real-time data analysis platforms, reflecting a comprehensive strategy to revolutionize cancer care.

Clinical pioneers at UC San Diego emphasize the potential impact of this research in overcoming the limitations of current treatment paradigms. Dr. Diane Simeone, director of the UC San Diego Moores Cancer Center, articulates how these technological advancements resonate with the institutional mission to transform healthcare delivery by harnessing precision medicine’s full potential. The integration of digital tumor models into clinical workflows promises a future where therapeutic misalignments are drastically reduced, and cure rates for advanced malignancies improve markedly.

Moreover, the continuous integration of novel data streams—ranging from genomic sequencing to patient electronic health records—enables the DREs to learn from an expanding corpus of cancer cases, thus refining predictive accuracy over time. The adaptability of these systems to evolving biological data patterns ensures clinical recommendations remain current, which is crucial in the rapidly shifting oncologic landscape where resistance mutations and immune evasion tactics frequently arise.

From a translational science perspective, the successful implementation of these adaptive digital tumor frameworks could set a new gold standard in oncology. By mechanistically simulating tumor evolution and pharmacodynamics, such platforms hold the promise of expediting drug development, informing combination therapies, and fostering precision clinical trials that dynamically personalize treatment arms based on interim digital tumor model readouts.

In summary, UC San Diego’s leadership in the ARPA-H-supported "Dynamic Digital Tumors for Precision Oncology" project represents a pioneering stride toward integrating AI-driven digital twin technologies in cancer treatment. The initiative tackles the longstanding challenge of tumor heterogeneity and therapeutic resistance by providing continuously adaptive, biologically informed treatment recommendations. This approach stands to transform oncologic care pathways, enhancing survival outcomes and quality of life for millions of patients confronting advanced cancers.

Subject of Research: Precision oncology and adaptive cancer treatment using AI-driven digital tumor modeling.

Article Title: UC San Diego Leads $23.6 Million ARPA-H Initiative to Develop AI-Powered Digital Tumors for Personalized Cancer Therapy.

News Publication Date: [Not Provided]

Web References: https://arpa-h.gov/news-and-events/arpa-h-pioneers-game-changing-cancer-care-designed-adapt-throughout-treatment

Image Credits: UC San Diego Health Sciences/University Communications

Keywords: Cancer, Artificial intelligence, Technology, Precision oncology, Adaptive therapy, Digital tumor modeling, Drug recommender engines, Tumor evolution, Machine learning, Personalized medicine

Addressing this critical bottleneck, a pioneering research team led by Ma, J., Laune, M., and Li, P. has introduced an innovative platform dubbed the Airborne Biomarker Localization Engine (ABLE). This breakthrough technology promises to transform how we detect and analyze airborne biomarkers by enabling the collection and concentration of trace molecular and particulate species directly from open air within a remarkably short timeframe of approximately fifteen minutes. The implications extend across diverse fields—including remote healthcare diagnostics, rapid pathogen detection in public environments, and food safety inspection—offering a compelling alternative to existing techniques reliant on cumbersome and costly mass spectrometry equipment typically confined to specialist laboratories.

Traditional airborne biomarker detection methodologies suffer from fundamental limitations primarily due to the low concentration and volatility of target molecules and particles. Mass spectrometry, the gold standard for sensitive detection, necessitates elaborate sample preparation, sophisticated vacuum systems, and controlled environments, all of which restrict accessibility and portability. ABLE circumvents these barriers by ingeniously employing a multiphase condensation approach that amplifies dilute gaseous biomarkers into concentrated aqueous droplets. This phase conversion not only enhances detectability but also creates a versatile sample format that can be interrogated using common liquid-phase biosensing platforms, heralding a new era in point-of-care diagnostics.

At the heart of ABLE’s technology lies its unique method for inducing controlled water condensation directly from ambient air. By exploiting subtle variations in temperature and humidity, the system nucleates microdroplets that encapsulate airborne biomarkers with high efficiency. Rather than passively collecting aerosols or vapor, ABLE actively transforms the detection milieu, erecting microenvironments within droplets that localize and stabilize target analytes. This condensation-driven approach represents a paradigm shift, fundamentally elevating the concentration of biomarkers in a physically accessible medium while preserving their chemical integrity for subsequent analysis.

Beyond its innovative concentration mechanism, ABLE also benefits from a remarkable stability observed in condensate-trapped biomarkers. Extensive fundamental studies into the physicochemical properties of these microdroplets reveal an unexpected resistance to degradation and volatilization, factors that traditionally compromise airborne sampling. This finding is pivotal because it extends the viable analytical window, allowing for delayed or transportable analysis without significant loss of signal fidelity. Such stability also affords compatibility with a wide array of existing liquid-phase assays, expanding ABLE’s adaptability to different detection schemes and biomarker classes.

ABLE’s versatility encompasses detection of both volatile organic compounds (VOCs) and non-volatile particulate matter—a critical advantage given the diverse nature of airborne biomarkers. VOCs, often indicative of metabolic processes or pathogen presence, have historically been challenging to assay directly due to their rapid diffusion and chemical reactivity. By converting VOCs into aqueous droplets, ABLE essentially “immobilizes” these volatile species, enabling detection techniques that require liquid samples. Simultaneously, particulate biomarkers such as airborne proteins, nucleic acids, or cellular debris are naturally entrapped and concentrated within the condensate. This dual-functionality dramatically broadens the scope of environmental and health surveillance applications.

The platform’s design prioritizes simplicity and portability, qualities essential for deployment outside specialized laboratory settings. ABLE’s compact form factor and user-friendly operation mean that it can be employed in remote or resource-limited environments without extensive technical training or infrastructure. This accessibility aligns with emerging trends in decentralized healthcare, where early detection and rapid diagnostics can have profound impacts on disease management and public health outcomes, especially during outbreaks or in vulnerable populations such as infants and the elderly.

In practical demonstrations, ABLE has successfully detected a range of biomarkers relevant to infant health monitoring. Non-contact diagnosis of respiratory infections or metabolic disorders in neonates—often challenging or risky when involving invasive sampling—becomes feasible with this platform. Such applications could revolutionize neonatal care by enabling continuous monitoring in home or clinical settings, reducing the need for hospital visits, and minimizing exposure to infectious agents.

Equally transformative are ABLE’s applications in public pathogen surveillance, particularly in crowded spaces or transportation hubs where airborne pathogens pose significant transmission risks. The ability to rapidly detect airborne bacterial or viral markers with portable equipment could empower health authorities to implement timely interventions, monitor outbreak dynamics in real time, and enhance biosecurity without reliance on centralized laboratories or delayed testing cycles.

Food safety monitoring also stands to benefit substantially from ABLE’s capabilities. Detection of airborne contaminants, spoilage indicators, or allergenic molecules in food processing and retail environments can mitigate risks early and efficiently. Given that airborne cross-contamination is a critical vector for foodborne illnesses, rapid, onsite testing facilitated by ABLE could improve compliance with safety standards and protect consumer health more effectively than traditional batch testing.

The fundamental research underpinning ABLE’s operation offers new scientific insights into multiphase condensation phenomena. The team’s precise characterizations of droplet formation kinetics, analyte partitioning, and microdroplet stability expand our understanding of aerosol chemistry and bioaerosol dynamics, fields with growing importance in environmental science and public health. These insights not only validate ABLE’s technological approach but also open avenues for further optimization and customization for specific biomarker targets or environmental conditions.

Furthermore, ABLE’s integration potential with existing liquid-sensing platforms underscores its strategic value. Many biosensors, including immunoassays, enzymatic tests, and nucleic acid amplification methods, operate in aqueous phases and thus can be seamlessly interfaced with the condensate samples produced by ABLE. This interoperability reduces development time and costs while leveraging the extensive biosensor ecosystem already in place, facilitating faster translation from experimental setups to real-world deployment.

Crucially, the affordability of ABLE enhances its prospects for widespread adoption. By eschewing the need for expensive and bulky instrumentation typical of mass spectrometry and chromatographic systems, it democratizes access to advanced airborne biomarker detection. This democratization is key to scaling up surveillance networks, empowering individual users and communities with actionable health information, and fostering a more responsive public health infrastructure worldwide.

In summary, the Airborne Biomarker Localization Engine represents a transformative technological leap in the field of airborne biosensing. By merging innovative multiphase condensation chemistry with practical design considerations, ABLE overcomes the longstanding challenge of airborne biomarker dilution and instabilities. Its ability to quickly and reliably convert trace airborne molecules into concentrated liquid samples suitable for existing biosensing assays could redefine how we approach non-invasive health monitoring, infectious disease control, and environmental safety in open-air contexts.

The vision implicit in ABLE’s development aligns strongly with the future of personalized and population health—where sensitive diagnostics transcend the confines of clinical laboratories and become seamlessly embedded in everyday environments. As ongoing research refines its capabilities and broadens its applications, ABLE stands poised to become a cornerstone technology in meeting the global demand for rapid, accessible, and accurate biomarker detection outside traditional settings.

Looking ahead, potential iterations of ABLE could incorporate automated sample handling, multiplexed detection arrays, and wireless communication modules, further enhancing its utility in real-time surveillance networks and telemedicine frameworks. The current achievements foreshadow a new generation of biosensing tools that leverage physical chemistry and bioengineering ingenuity to unlock the diagnostic potential of the air we breathe, fundamentally reshaping our relationship with health and environment.

—

Article Title:
Airborne biomarker localization engine for open-air point-of-care detection

Article References:
Ma, J., Laune, M., Li, P. et al. Airborne biomarker localization engine for open-air point-of-care detection.
Nat Chem Eng (2025). https://doi.org/10.1038/s44286-025-00223-9

Image Credits: AI Generated